Drug Profile
Immune globulin - OMRIX Viopharmaceuticals
Alternative Names: Immune deficiency immune globulin therapy - Omrix; Immunoglobulin intravenous - Omrix; Intravenous immunoglobulin - Omrix; Omr-IgG-am; Omr-IgG-am™-IVIGLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Autoimmune disorders; Immunodeficiency disorders
Most Recent Events
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
- 28 Sep 2006 IVIG has been licensed to FFF enterprises in the US